{"id":6225,"date":"2015-12-08T13:12:13","date_gmt":"2015-12-08T12:12:13","guid":{"rendered":"http:\/\/news.embl.de\/?p=6225"},"modified":"2024-04-19T16:02:35","modified_gmt":"2024-04-19T14:02:35","slug":"1512-target-validation","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/","title":{"rendered":"Target Validation platform launches"},"content":{"rendered":"\n<p>Establishing the validity of an association between a disease and biological target for a drug can be extremely challenging and expensive. To address this challenge, the CTTV, a collaboration between GSK, the Wellcome Trust Sanger Institute and EMBL-EBI, has created a web-based platform (<a href=\"http:\/\/www.targetvalidation.org\/\">www.targetvalidation.org<\/a>) that draws on public data resources to help drug discovery. This state-of-the-art web interface will allow researchers to access thousands of target profiles summarising the evidence for the involvement of a specific gene product with a disease.<\/p>\n\n\n\n<p>\u201cThe huge growth in human genetic and genomic data has transformed research in a very short space of time, but there is a gap between basic and translational research,\u201d explains Jeff Barrett, Director of the CTTV. \u201cWe have learned so much about the links between genes, tissue function and disease, and we need solid partnerships like the CTTV to make sure that knowledge makes it to the people who make medicines. The Target Validation platform is all about enabling communities to work together, making the hand-off from basic research to drug discovery smoother.\u201d<\/p>\n\n\n\n<p>The Target Validation Platform provides a single, robust infrastructure that integrates high-level information from key sources of evidence covering common and rare disease genetics, somatic mutations in cancer, tissue and cellular expression patterns, information mined from published scientific literature, approved drugs, reaction pathways and animal models. Co-designed with biologists, it is easy to search by target, disease or therapeutic area.<\/p>\n\n\n<blockquote\n\n\nclass=\"vf-blockquote\">We need solid partnerships like the CTTV to make sure that knowledge makes it to the people who make medicines.<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\">Validating effective targets<\/h3>\n\n\n\n<p>\u201cOur ability to identify and validate effective targets can mean the difference between developing a new medicine successfully or wasting valuable time and resources pursuing dead ends,\u201d says Lon Cardon, Senior Vice-President of GSK R&amp;D. \u201cThe collaborative work under way at the Centre for Therapeutic Target Validation provides a real opportunity for us to make a profound impact on attrition and, even more importantly, to tackle unexpected pathways for new medicine. The launch of this new open access platform is a major step in how we\u2019ll truly open up the discoveries made through this collaboration to benefit the broader scientific community.\u201d<\/p>\n\n\n\n<p>\u201cWe worked very closely with biologists working in different environments to make sure the platform would be both useful and intuitive,\u201d says Ian Dunham, Scientific Director of the CTTV. \u201cToday we\u2019ve launched a service that provides evidence for over 21,800 targets, with more than 8800 structured disease and clinical phenotype terms \u2013 but we expect those numbers to grow substantially as we integrate CTTV experimental project data.\u201d<\/p>\n\n\n<blockquote\n\n\nclass=\"vf-blockquote\">Evidence for over 21,800 targets, with more than 8800 structured disease and clinical phenotype terms.<\/blockquote>\n\n\n\n<p>\u201cThe CTTV enables researchers in academia to work with industry, bringing the research bases together in a precompetitive environment to deliver insight into the genomics underlying disease. The databases and analytical methods developed will increase our knowledge of the biological targets of diseases to help advance treatments,\u201d says Professor Sir Mike Stratton, Director of the Sanger Institute.<\/p>\n\n\n\n<p>\u201cThe CTTV is already transforming research in drug discovery through its specific integration,\u201d says Ewan Birney, Director of EMBL-EBI. \u201cWe are delighted at how CTTV has leveraged the high-quality data from EMBL-EBI, providing integration and visualisation for both commercial and academic users, and we\u2019re looking forward to seeing the community use this platform in earnest.\u201d<\/p>\n\n\n\n<p>The CTTV welcomes anyone who is interested in finding connections between genes and diseases to try the platform and <a href=\"mailto:support@targetvalidation.org\">share their feedback<\/a>.<\/p>\n\n\n\n<p><em>This post was originally published on <a href=\"https:\/\/www.ebi.ac.uk\/about\/news\/press-releases\/target-validation-platform-launches\" target=\"_blank\" rel=\"canonical nofollow noopener noreferrer\" data-href=\"https:\/\/www.ebi.ac.uk\/about\/news\/press-releases\/target-validation-platform-launches\">EMBL-EBI News.<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Identifying evidence-based relationships between drug targets and diseases.<\/p>\n","protected":false},"author":13,"featured_media":6226,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[17595,3],"tags":[368,153,36,155,32,71,25],"embl_taxonomy":[],"class_list":["post-6225","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-connections","category-lab-matters","tag-birney","tag-cttv","tag-embl-ebi","tag-gsk","tag-health","tag-industry","tag-partnerships"],"acf":{"article_intro":"<p>The Centre for Therapeutic Target Validation (CTTV) has launched\u00a0<a href=\"https:\/\/www.targetvalidation.org\/\">a new web platform<\/a> for life-science researchers that helps them identify therapeutic targets for new and repurposed medicines. Today\u2019s launch underscores the CTTV\u2019s commitment to share its data openly to benefit the broader scientific community.<\/p>\n","related_links":[{"link_description":"Centre for Therapeutic Target Validation (CTTV)","link_url":"https:\/\/www.targetvalidation.org\/"},{"link_description":"CTTV appoints Jeff Barrett as founding Director, EMBLetc, 27 February 2015","link_url":"http:\/\/news.embl.de\/lab-matters\/1502-barrett-cttv\/"},{"link_description":"This article first appeared as a press release on the EMBL-EBI website, 8 December 2015","link_url":"http:\/\/www.ebi.ac.uk\/about\/news\/press-releases\/target-validation-platform-launches"}],"article_sources":false,"vf_locked":false,"featured":false,"color":"#007B53"},"embl_taxonomy_terms":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Target Validation platform launches | EMBL<\/title>\n<meta name=\"description\" content=\"CTTV Target Validation Platform provides evidence for over 21,800 therapeutic targets, spanning more than 8800 diseases and phenotypes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Target Validation platform launches | EMBL\" \/>\n<meta property=\"og:description\" content=\"CTTV Target Validation Platform provides evidence for over 21,800 therapeutic targets, spanning more than 8800 diseases and phenotypes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:author\" content=\"www.facebook.com\/EMBLEBI\" \/>\n<meta property=\"article:published_time\" content=\"2015-12-08T12:12:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-19T14:02:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/12\/CTTV_Launch_EMBL.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"445\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Mary Todd Bergman\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@EMBLEBI\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mary Todd Bergman\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/\"},\"author\":{\"name\":\"Mary Todd Bergman\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/052a43af2beb3860bffa67c0f0474875\"},\"headline\":\"Target Validation platform launches\",\"datePublished\":\"2015-12-08T12:12:13+00:00\",\"dateModified\":\"2024-04-19T14:02:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/\"},\"wordCount\":555,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/12\/CTTV_Launch_EMBL.jpg\",\"keywords\":[\"birney\",\"cttv\",\"embl-ebi\",\"gsk\",\"health\",\"industry\",\"partnerships\"],\"articleSection\":[\"Connections\",\"Lab Matters\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/\",\"url\":\"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/\",\"name\":\"Target Validation platform launches | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/12\/CTTV_Launch_EMBL.jpg\",\"datePublished\":\"2015-12-08T12:12:13+00:00\",\"dateModified\":\"2024-04-19T14:02:35+00:00\",\"description\":\"CTTV Target Validation Platform provides evidence for over 21,800 therapeutic targets, spanning more than 8800 diseases and phenotypes.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/12\/CTTV_Launch_EMBL.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/12\/CTTV_Launch_EMBL.jpg\",\"width\":620,\"height\":445,\"caption\":\"New web interface, launched by GSK, EMBL-EBI and Wellcome Trust Sanger Institute. IMAGE: EMBL-EBI\/Spencer Phillips\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/052a43af2beb3860bffa67c0f0474875\",\"name\":\"Mary Todd Bergman\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/61b3547fb0d7b56f0de2f0800bbfe2be156d2497f70f754bde9028f71fd85683?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/61b3547fb0d7b56f0de2f0800bbfe2be156d2497f70f754bde9028f71fd85683?s=96&d=mm&r=g\",\"caption\":\"Mary Todd Bergman\"},\"description\":\"Mary Todd Bergman is the Senior Communications Officer at EMBL-EBI. She is surrounded by people who have a calling and love what they do, and helps them spread the word about it. Who could ask for more?\",\"sameAs\":[\"http:\/\/www.ebi.ac.uk\",\"www.facebook.com\/EMBLEBI\",\"https:\/\/x.com\/EMBLEBI\"],\"url\":\"https:\/\/www.embl.org\/news\/author\/mary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Target Validation platform launches | EMBL","description":"CTTV Target Validation Platform provides evidence for over 21,800 therapeutic targets, spanning more than 8800 diseases and phenotypes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/","og_locale":"en_US","og_type":"article","og_title":"Target Validation platform launches | EMBL","og_description":"CTTV Target Validation Platform provides evidence for over 21,800 therapeutic targets, spanning more than 8800 diseases and phenotypes.","og_url":"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_author":"www.facebook.com\/EMBLEBI","article_published_time":"2015-12-08T12:12:13+00:00","article_modified_time":"2024-04-19T14:02:35+00:00","og_image":[{"width":620,"height":445,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/12\/CTTV_Launch_EMBL.jpg","type":"image\/jpeg"}],"author":"Mary Todd Bergman","twitter_card":"summary_large_image","twitter_creator":"@EMBLEBI","twitter_site":"@embl","twitter_misc":{"Written by":"Mary Todd Bergman","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/"},"author":{"name":"Mary Todd Bergman","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/052a43af2beb3860bffa67c0f0474875"},"headline":"Target Validation platform launches","datePublished":"2015-12-08T12:12:13+00:00","dateModified":"2024-04-19T14:02:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/"},"wordCount":555,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/12\/CTTV_Launch_EMBL.jpg","keywords":["birney","cttv","embl-ebi","gsk","health","industry","partnerships"],"articleSection":["Connections","Lab Matters"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/","url":"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/","name":"Target Validation platform launches | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/12\/CTTV_Launch_EMBL.jpg","datePublished":"2015-12-08T12:12:13+00:00","dateModified":"2024-04-19T14:02:35+00:00","description":"CTTV Target Validation Platform provides evidence for over 21,800 therapeutic targets, spanning more than 8800 diseases and phenotypes.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/lab-matters\/1512-target-validation\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/12\/CTTV_Launch_EMBL.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/12\/CTTV_Launch_EMBL.jpg","width":620,"height":445,"caption":"New web interface, launched by GSK, EMBL-EBI and Wellcome Trust Sanger Institute. IMAGE: EMBL-EBI\/Spencer Phillips"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/052a43af2beb3860bffa67c0f0474875","name":"Mary Todd Bergman","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/61b3547fb0d7b56f0de2f0800bbfe2be156d2497f70f754bde9028f71fd85683?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/61b3547fb0d7b56f0de2f0800bbfe2be156d2497f70f754bde9028f71fd85683?s=96&d=mm&r=g","caption":"Mary Todd Bergman"},"description":"Mary Todd Bergman is the Senior Communications Officer at EMBL-EBI. She is surrounded by people who have a calling and love what they do, and helps them spread the word about it. Who could ask for more?","sameAs":["http:\/\/www.ebi.ac.uk","www.facebook.com\/EMBLEBI","https:\/\/x.com\/EMBLEBI"],"url":"https:\/\/www.embl.org\/news\/author\/mary\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/12\/CTTV_Launch_EMBL.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2015\/12\/CTTV_Launch_EMBL.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/6225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=6225"}],"version-history":[{"count":7,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/6225\/revisions"}],"predecessor-version":[{"id":20113,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/6225\/revisions\/20113"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/6226"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=6225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=6225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=6225"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=6225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}